Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is now crowded and full of potholes. Drug hunters need to look ahead, beyond the discovery process itself, to the reality of the many impediments that will confront drug candidates as they proceed towards the clinic in today's landscape. Here, I present three insights from current events, the third one taking a contrarian position.
Chinese biopharmaceutical industry investment landscape has been marked by a new record -- USD $260M Series D investment raised by Innovent Biologics, Inc. exceeded China's previous investment deals for biopharmaceutical industry and became one of the largest biopharmaceutical industry fundraising events in the world for both private and public financing markets in 2016.